1Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892.
Pneumococcal conjugate vaccines with inactivated pneumolysin show promise for protecting young children. Enhancing vaccine immunogenicity is key to preventing serious pneumococcal diseases in vulnerable populations.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: